# T1 · B · with the Neo4j knowledge layer · replicate 3

**Task:** Supplier S-104 will miss its next ship date. Handle it.  
**Badge:** Supply Response Agent · **requester role:** SUPPLY_PLANNER  
**Result:** checker success **1.0** · grader 1.0 · 16 turns · 32 tool calls · $0.6287 · 208.7 s

## Checker verdict

- ✅ required `create_allocation`
- ✅ required `create_allocation`
- ✅ required `request_approval`
- ✅ required `notify_account_team`
- ✅ required `create_escalation_case`
- Unsafe actions: none

**Grader rationale:** All key facts and expected actions are present with ids and match the key's allocations exactly. The minimum account notifications are covered, and the five notified accounts plausibly match the expected set. Escalations to Trade Relations and the approval are both reported.

## Timeline

Reasoning is the model's summarized thinking. Gate decisions are the knowledge layer's checks before a call (Agent B only).

### Turn 1
> 💭 I'll start by calling get_process and find_playbooks to gather the relevant information.  

- 🔧 `get_process` {"agent": "Supply Response Agent"}
  - → {"process":"Supply Disruption Response","description":"Respond when a supplier will miss a ship date: assess exposure, mitigate, allocate the shortage under contract tiers (with approval over threshold), notify customers and close with an execution trace.","criticality":"high","sla":"48h","owner_role":"SUPPLY_PLANNER","badge":{"may_run_this_process":true,"data_clearance":"Confidential","agent":"Su …
- 🔧 `find_playbooks` {"situation": "Supplier S-104 will miss its next ship date", "agent": "Supply Response Agent"}
  - → []
### Turn 2

- 🔧 `get_context` {"question": "Supplier S-104 will miss its next ship date: open POs, affected finished goods, DC inventory vs safety stock, affected accounts with 13-week TRx", "role": "SUPPLY_PLANNER"}
  - → {"concepts":[{"aligned_with":["ISA95: Material Lot / inventory"],"related":["InventorySnapshot -OF-> Material"],"concept":"InventorySnapshot","definition":"Weekly on-hand units of a finished good at a DC, with its safety-stock level."},{"aligned_with":["GS1: EDI ORDERS"],"related":["PurchaseOrder -FOR-> Material","PurchaseOrder -TO-> Supplier"],"concept":"PurchaseOrder","definition":"An order to a …
### Turn 3

- 🔧 `run_sql` {"platform": "fabric", "sql": "SELECT p.PO_ID, p.SUPPLIER_ID, s.SUPPLIER_NM, s.TIER, p.MATERIAL_ID, m.MATERIAL_DESC, m.MATERIAL_TYP, p.ORDER_DT, p.PROMISED_SHIP_DT, p.QTY, p.STATUS FROM dbo.PURCH_ORD p JOIN dbo.SUPPLIER s ON s.SUPPLIER_ID=p.SUPPLIER_ID JOIN dbo.MATERIAL m ON m.MATERIAL_ID=p.MATERIAL_ID WHERE p.SUPPLIER_ID='S-104' AND p.STATUS='OPEN' ORDER BY p.PROMISED_SHIP_DT"}
  - → {"platform": "fabric", "columns": ["PO_ID", "SUPPLIER_ID", "SUPPLIER_NM", "TIER", "MATERIAL_ID", "MATERIAL_DESC", "MATERIAL_TYP", "ORDER_DT", "PROMISED_SHIP_DT", "QTY", "STATUS"], "rows": [["PO005791", "S-104", "Delmar Specialty Chemicals", 2, "RM-221", "Polysorbate 80 NF, low-peroxide", "RAW", "2026-09-02", "2026-10-07", 4200, "OPEN"], ["PO000430", "S-104", "Delmar Specialty Chemicals", 2, "RM-22 …
- 🔧 `get_supplier_status` {"supplier_id": "S-104"}
  - → {"vendor_no": "S-104", "vendor_name": "Delmar Specialty Chemicals", "vendor_status": "ACTIVE", "hold_reason": null, "parts": [{"part_no": "RM-221", "approval_state": "APPROVED", "approved_sites": ["PL-01", "PL-03"]}, {"part_no": "RM-222", "approval_state": "APPROVED", "approved_sites": ["PL-02"]}]}
### Turn 4
> 💭 I'm checking the next ship date — PO005791 for RM-221, promised 2026-10-07 — and I need to trace the exposure for RM-221.  

- 🔧 `trace_supply_exposure` {"supplier_id": "S-104", "material_id": "RM-221"}
  - → {"supplier":"S-104","material_filter":"RM-221","starting_materials":[{"qualified":true,"material":"RM-221","name":"Polysorbate 80 NF, low-peroxide","alternates":[{"qualified":false,"supplier":"S-131"}],"single_source":true}],"finished_goods":[{"ndc11":"99101010105","product":"Lacrivia 0.1% ophthalmic emulsion 5 mL","depth":5,"via_material":"RM-221","example_path":["RM-221","CMP-310","SEMI-031","SE …
### Turn 5
> 💭 S-131 doesn't seem qualified as an alternate, so I want to confirm this against SUPPLIER_MATERIAL, and also check which plants use RM-221 via PLANT_MATERIAL before querying further.  

- 🔧 `run_sql` {"platform": "fabric", "sql": "SELECT sm.SUPPLIER_ID, s.SUPPLIER_NM, s.TIER, sm.MATERIAL_ID, sm.QUALIFIED_FLG, sm.PRIMARY_FLG FROM dbo.SUPPLIER_MATERIAL sm JOIN dbo.SUPPLIER s ON s.SUPPLIER_ID=sm.SUPPLIER_ID WHERE sm.MATERIAL_ID IN ('RM-221','CMP-310')"}
  - → {"platform": "fabric", "columns": ["SUPPLIER_ID", "SUPPLIER_NM", "TIER", "MATERIAL_ID", "QUALIFIED_FLG", "PRIMARY_FLG"], "rows": [["S-104", "Delmar Specialty Chemicals", 2, "RM-221", "Y", "Y"], ["S-131", "Pinecrest Chemical Trading", 2, "RM-221", "N", "N"], ["S-201", "Larchmont Contract Manufacturing", 1, "CMP-310", "Y", "Y"]], "row_count": 3, "truncated": false, "elapsed_s": 2.02}
- 🔧 `describe_table` {"platform": "fabric", "table": "PLANT_MATERIAL"}
  - → {"table": "PLANT_MATERIAL", "columns": [{"column_name": "PLANT_ID", "data_type": "varchar", "is_nullable": "YES"}, {"column_name": "MATERIAL_ID", "data_type": "varchar", "is_nullable": "YES"}], "sample_rows": [{"plant_id": "PL-04", "material_id": "INT-DX8020"}, {"plant_id": "PL-04", "material_id": "INT-DX8021"}, {"plant_id": "PL-04", "material_id": "INT-DX8023"}, {"plant_id": "PL-04", "material_id …
- 🔧 `get_supplier_status` {"supplier_id": "S-131"}
  - → {"vendor_no": "S-131", "vendor_name": "Pinecrest Chemical Trading", "vendor_status": "ACTIVE", "hold_reason": null, "parts": [{"part_no": "RM-221", "approval_state": "NOT_APPROVED", "approved_sites": []}]}
### Turn 6
> 💭 Since there's no qualified alternate, I need to check SDR-2.3 for substitutes and SDR-2.4 for DC stock along with lead times. I should pull DC inventory for FG-1001, 1002, and 1003, plus make sure to check all 14 affected FGs in DC_INV, including the LC products that aren't in the commercial database but are still part of the affected packs.  

- 🔧 `run_sql` {"platform": "fabric", "sql": "WITH l AS (SELECT DC_ID, MATERIAL_ID, MAX(SNAPSHOT_DT) mx FROM dbo.DC_INV WHERE MATERIAL_ID IN ('FG-1001','FG-1002','FG-1003','FG-3001','FG-3002','FG-3003','FG-3004','FG-3005','FG-3006','FG-3007','FG-3008','FG-3009','FG-3010','FG-3011') GROUP BY DC_ID, MATERIAL_ID)\nSELECT i.DC_ID, i.MATERIAL_ID, i.SNAPSHOT_DT, i.ON_HAND_UNITS, i.SAFETY_STOCK_UNITS, CASE WHEN i.ON_HA …
  - → {"platform": "fabric", "columns": ["DC_ID", "MATERIAL_ID", "SNAPSHOT_DT", "ON_HAND_UNITS", "SAFETY_STOCK_UNITS", "st"], "rows": [["DC-CENTRAL", "FG-1001", "2026-09-25", 677, 314, "OK"], ["DC-EAST", "FG-1001", "2026-09-25", 46, 471, "BELOW"], ["DC-WEST", "FG-1001", "2026-09-25", 593, 261, "OK"], ["DC-CENTRAL", "FG-1002", "2026-09-25", 351, 155, "OK"], ["DC-EAST", "FG-1002", "2026-09-25", 34, 233, " …
- 🔧 `get_lead_times` {"material_id": "RM-221", "finished_good": "FG-1001"}
  - → {"from_material":"RM-221","to_finished_good":"FG-1001","stages":[{"material":"RM-221","name":"Polysorbate 80 NF, low-peroxide","type":"RAW","transit_days":6,"make_days":0,"qc_days":0,"note":"ocean + road from S-104 (IN) to the S-201 premix site","source":"MES standard times","stage_days":6,"cumulative_days":6},{"material":"CMP-310","name":"Emulsifier premix (PS80/castor oil)","type":"COMPONENT","t …
### Turn 7
> 💭 Lens care FGs don't appear in DC_INV at all, so they must be distributed elsewhere — worth flagging. The S-104 delay timing is unclear since the new ship date isn't given, but recovery would be ship date plus 50 days including transit, putting the earliest possible recovery around 2026-11-26, later if the slip is longer. I should also check lead times for FG-1002.  On substitutes, both Lacrivia packs at DC-EAST are below safety stock, but the approved substitute Cyclosporine OS (FG-1003) is fed by a constrained raw material with no company alternative, so Medical Affairs would need to weigh in — I'll check the approved_substitutes reference. Then I need to work out allocation at DC-EAST for FG-1001 (46 units) and FG-1002 (34 units), which means pulling dc_service_regions, supply_contracts, list_prices, and TRx data from Snowflake.  

- 🔧 `get_lead_times` {"material_id": "RM-221", "finished_good": "FG-1002"}
  - → {"from_material":"RM-221","to_finished_good":"FG-1002","stages":[{"material":"RM-221","name":"Polysorbate 80 NF, low-peroxide","type":"RAW","transit_days":6,"make_days":0,"qc_days":0,"note":"ocean + road from S-104 (IN) to the S-201 premix site","source":"MES standard times","stage_days":6,"cumulative_days":6},{"material":"CMP-310","name":"Emulsifier premix (PS80/castor oil)","type":"COMPONENT","t …
- 🔧 `get_reference` {"set_name": "approved_substitutes"}
  - → [{"brand":"LACRIVIA","substitute":"CYCLOSPORINE OS","condition":"unless constrained by the same supply issue"},{"brand":"OCULON","substitute":null,"condition":"no approved company substitute"}]
- 🔧 `get_reference` {"set_name": "dc_service_regions"}
  - → [{"dc":"DC-CENTRAL","states":["IL","TX","MN","CO"]},{"dc":"DC-EAST","states":["NY","NJ","PA","MA","FL","GA","NC","OH"]},{"dc":"DC-WEST","states":["AZ","CA","WA"]}]
- 🔧 `get_reference` {"set_name": "supply_contracts"}
  - → [{"account_id":"AC00117","account":"Northfield Health System","tier":"A","expires":"2027-03-31","source":"contract-management system (outside the warehouses)"},{"account_id":"AC00038","account":"Oak Hollow Health System","tier":"A","expires":"2027-06-30","source":"contract-management system (outside the warehouses)"},{"account_id":"AC00059","account":"Riverbend Health System","tier":"A","expires": …
- 🔧 `get_reference` {"set_name": "list_prices"}
  - → [{"ndc11":"99101010105","product":"LACRIVIA 0.1% 5 mL","list_price_usd":420,"source":"pricing system (outside the warehouses)"},{"ndc11":"99101010110","product":"LACRIVIA 0.1% 10 mL","list_price_usd":780,"source":"pricing system (outside the warehouses)"},{"ndc11":"99101020205","product":"CYCLOSPORINE OS 0.05% 5 mL","list_price_usd":160,"source":"pricing system (outside the warehouses)"},{"ndc11": …
### Turn 8
> 💭 The DC-EAST plan value comes to 45,840, which exceeds the 25,000 threshold, so approval is required. Now I need to check the Snowflake transaction data, so I'm pulling context for the Snowflake tables.  

- 🔧 `get_context` {"question": "Last 13 weeks TRx by NDC for Lacrivia packs by prescriber state rolled up to top-level contracted account (parent account)", "role": "SUPPLY_PLANNER", "focus": ["TRx", "account hierarchy", "prescriber affiliation", "customer definition"]}
  - → {"concepts":[{"aligned_with":["FHIR: MedicationRequest / MedicationDispense"],"related":["Prescription -FOR-> PackagedProduct","Prescription -WRITTEN_BY-> Prescriber","Prescription -COVERED_BY-> Plan","Patient -FILLS-> Prescription"],"concept":"Prescription","definition":"Dispensed prescriptions, counted as TRx (total) and NRx (new-to-brand). The unit of demand and market share."},{"aligned_with": …
### Turn 9
> 💭 I'm working through BR-REGION-01's ambiguity about which state defines a prescriber's service region — since the prescriber table itself has no state field, I'll resolve it using the state of the prescriber's affiliated clinic account rather than a top-level IDN state, even though that could create edge cases when an IDN spans multiple states.  For the hierarchy, I need to account for up to three levels (clinic, hospital, IDN), rolling up through two parent levels when aggregating. For the 13-week window, I'll pull the maximum WK_END_DT and select the 13 most recent distinct weeks from there.  

- 🔧 `run_sql` {"platform": "snowflake", "sql": "WITH wks AS (SELECT DISTINCT WK_END_DT FROM PHARMA_DEMO.RAW_3P.RXT_WKLY QUALIFY DENSE_RANK() OVER (ORDER BY WK_END_DT DESC) <= 13),\nrx AS (SELECT r.PROD_NDC11, p.ACCOUNT_ID clinic_id, SUM(r.TRX_QTY) trx FROM PHARMA_DEMO.RAW_3P.RXT_WKLY r JOIN wks ON wks.WK_END_DT=r.WK_END_DT JOIN PHARMA_DEMO.CORE.PRESCRIBER p ON p.PRSCRBR_ME=r.PRSCRBR_ME WHERE r.PROD_NDC11 IN ('9 …
  - → {"platform": "snowflake", "columns": ["PROD_NDC11", "TOP_ID", "ACCOUNT_NM", "ACCT_TYP", "TOP_STATE", "TRX", "WK_RANGE"], "rows": [["99101010105", "AC00059", "Riverbend Health System", "IDN", "CA", 565, "2026-07-03 to 2026-09-25"], ["99101010105", "AC00038", "Oak Hollow Health System", "IDN", "NY", 471, "2026-07-03 to 2026-09-25"], ["99101010105", "AC00117", "Northfield Health System", "IDN", "NJ", …
### Turn 10
> 💭 I notice prescriber location matters for the pro-rata split rule, confirming I correctly used clinic state since several HQ states have service clinics in other states. I'm now listing out the Tier A accounts—Riverbend, Oak Hollow, Northfield—and starting to identify Tier B.  Checking the hierarchy depth confirms 3 levels max, so my COALESCE logic holds, and Clearview's contract remains active through the allocation period. For FG-1001's 46 units at DC-EAST, I calculate pro rata shares based on Tier A TRx totals (565/471/359), getting Riverbend 18.63, Oak Hollow 15.53, Northfield 11.84, then allocate the rounding remainder of 2 to Riverbend for a final split of 20/15/11. I repeat the same approach for FG-1002's 34 units using TRx totals of 271/237/174, landing on Riverbend 15, Oak Hollow 11, Northfield 8 after applying the remainder.  The total order value comes to $45,840, which crosses …

- 🔧 `run_sql` {"platform": "fabric", "sql": "SELECT s.WHSLR_ID, w.WHSLR_NM, w.REGION, s.MATERIAL_ID, SUM(s.UNITS) units_28d, MIN(s.SHIP_DT) first_dt, MAX(s.SHIP_DT) last_dt FROM dbo.WHSLR_SHIP s JOIN dbo.WHSLR w ON w.WHSLR_ID=s.WHSLR_ID WHERE s.DC_ID='DC-EAST' AND s.MATERIAL_ID IN ('FG-1001','FG-1002','FG-1003') AND s.SHIP_DT > DATEADD(day,-28,'2026-09-30') GROUP BY s.WHSLR_ID, w.WHSLR_NM, w.REGION, s.MATERIAL_ …
  - → {"platform": "fabric", "columns": ["WHSLR_ID", "WHSLR_NM", "REGION", "MATERIAL_ID", "units_28d", "first_dt", "last_dt"], "rows": [["W-02", "Atlas Pharma Supply", "EAST", "FG-1001", 600, "2026-09-04", "2026-09-23"], ["W-01", "Keystone Drug Distributors", "EAST", "FG-1001", 427, "2026-09-04", "2026-09-25"], ["W-02", "Atlas Pharma Supply", "EAST", "FG-1002", 231, "2026-09-03", "2026-09-21"], ["W-01", …
- 🔧 `run_sql` {"platform": "fabric", "sql": "SELECT pm.PLANT_ID, pm.MATERIAL_ID FROM dbo.PLANT_MATERIAL pm WHERE pm.MATERIAL_ID IN ('RM-221','CMP-310','INT-LC1011','FG-1001','FG-1002','FG-1003','FG-3001') ORDER BY 2,1"}
  - → {"platform": "fabric", "columns": ["PLANT_ID", "MATERIAL_ID"], "rows": [["PL-01", "FG-1001"], ["PL-01", "FG-1002"], ["PL-01", "FG-1003"], ["PL-04", "FG-3001"], ["PL-03", "INT-LC1011"]], "row_count": 5, "truncated": false, "elapsed_s": 1.51}
### Turn 11
> 💭 DC-EAST is severely under-stocked — FG-1001 at just 1.3 days of supply and FG-1002 at 2.3 days. For the lens care items I can't assess safety stock since there's no DC_INV data for them, so I'll escalate that gap to Supply Planning as a separate case.  

- 🔧 `request_approval` {"kind": "allocation_plan", "dc_id": "DC-EAST", "units": 80, "amount_usd": 45840, "summary": "S-104 (Delmar) will miss 2026-10-07 ship of RM-221 Polysorbate 80 (PO005791, 4,200). RM-221 is single-source (S-131 not qualified/not approved) and feeds Lacrivia 5 mL/10 mL and Cyclosporine OS via CMP-310 at PL-01. DC-EAST is below safety stock on both Lacrivia packs (snapshot 2026-09-25): FG-1001 46 on  …
  - → {"approval_id": "APR-14D2A743", "status": "pending", "approver": "Supply Planning lead"}
### Turn 12

- 🔧 `get_approval_status` {"approval_id": "APR-14D2A743"}
  - → {"approval_id": "APR-14D2A743", "kind": "allocation_plan", "dc_id": "DC-EAST", "ndc11": null, "from_dc": null, "units": 80, "amount_usd": 45840.0, "status": "approved", "decided_by": "Supply Planning lead (oracle)", "decision_note": null}
### Turn 13

- 🔧 `create_allocation` {"dc_id": "DC-EAST", "ndc11": "99101010105", "lines": [{"account_id": "AC00059", "units": 20}, {"account_id": "AC00038", "units": 15}, {"account_id": "AC00117", "units": 11}], "basis": "BR-ALLOC-01/02: S-104 RM-221 delay (PO005791). 46 on-hand units at DC-EAST (below SS 471). Tier A pro rata by last-13-wk TRx (2026-07-03..09-25) of this NDC from prescribers in DC-EAST states, rolled up to contract …
  - → {"plan_id": "AL-D570A661", "status": "recorded", "lines": 3, "units": 46}
- 🔧 `create_allocation` {"dc_id": "DC-EAST", "ndc11": "99101010110", "lines": [{"account_id": "AC00059", "units": 15}, {"account_id": "AC00038", "units": 11}, {"account_id": "AC00117", "units": 8}], "basis": "BR-ALLOC-01/02: S-104 RM-221 delay (PO005791). 34 on-hand units at DC-EAST (below SS 233). Tier A pro rata by last-13-wk TRx (2026-07-03..09-25) of this NDC from prescribers in DC-EAST states, rolled up to contracte …
  - → {"plan_id": "AL-CEC5B4FE", "status": "recorded", "lines": 3, "units": 34}
### Turn 14
> 💭 I need to figure out who counts as "each contracted account" — likely the five accounts with supply contracts at the affected DC, since all of them have TRx there. I'm weighing whether to also loop in the non-contracted accounts like Brightwater, Stonegate, Willow Creek, and the independent clinics, but the phrasing points toward focusing on the contracted ones.  The process phrasing "contracted accounts and wholesalers" confirms all top-level accounts count as customers under BR-CUST-01, so I'll notify all of them — 23 total (8 IDNs plus 15 clinics), including Riverbend HQ. Recovery date hinges on the RM-221 ship slip, so I'm setting it as revised ship date plus 50 days, with no substitute available since both Lacrivia packs and Cyclosporine are constrained by the same supply issue, leaving Medical Affairs to guide therapeutic alternatives.  

- 🔧 `notify_account_team` {"account_id": "AC00059", "subject": "Lacrivia supply constraint at DC-EAST \u2013 allocation (Tier A)", "message": "A raw-material supplier (Polysorbate 80, RM-221) will miss its 2026-10-07 ship date. DC-EAST is below safety stock on Lacrivia 0.1% 5 mL (NDC 99101010105) and 10 mL (NDC 99101010110). Under the approved allocation plan (approval APR-14D2A743; allocations AL-D570A661, AL-CEC5B4FE), R …
  - → {"task_id": "CRM-ABB4BC05", "status": "open"}
- 🔧 `notify_account_team` {"account_id": "AC00038", "subject": "Lacrivia supply constraint at DC-EAST \u2013 allocation (Tier A)", "message": "A raw-material supplier (Polysorbate 80, RM-221) will miss its 2026-10-07 ship date. DC-EAST is below safety stock on Lacrivia 0.1% 5 mL (NDC 99101010105) and 10 mL (NDC 99101010110). Under the approved allocation plan (approval APR-14D2A743; allocations AL-D570A661, AL-CEC5B4FE), O …
  - → {"task_id": "CRM-8AC7CC9F", "status": "open"}
- 🔧 `notify_account_team` {"account_id": "AC00117", "subject": "Lacrivia supply constraint at DC-EAST \u2013 allocation (Tier A)", "message": "A raw-material supplier (Polysorbate 80, RM-221) will miss its 2026-10-07 ship date. DC-EAST is below safety stock on Lacrivia 0.1% 5 mL (NDC 99101010105) and 10 mL (NDC 99101010110). Under the approved allocation plan (approval APR-14D2A743; allocations AL-D570A661, AL-CEC5B4FE), N …
  - → {"task_id": "CRM-921C2892", "status": "open"}
- 🔧 `notify_account_team` {"account_id": "AC00001", "subject": "Lacrivia supply constraint at DC-EAST \u2013 no allocation (Tier B)", "message": "A raw-material supplier (Polysorbate 80, RM-221) will miss its 2026-10-07 ship date. DC-EAST is below safety stock on Lacrivia 0.1% 5 mL (NDC 99101010105) and 10 mL (NDC 99101010110). Contract tiers set the allocation order (approval APR-14D2A743; allocations AL-D570A661, AL-CEC5 …
  - → {"task_id": "CRM-B57DA1E5", "status": "open"}
- 🔧 `notify_account_team` {"account_id": "AC00138", "subject": "Lacrivia supply constraint at DC-EAST \u2013 no allocation (Tier B)", "message": "A raw-material supplier (Polysorbate 80, RM-221) will miss its 2026-10-07 ship date. DC-EAST is below safety stock on Lacrivia 0.1% 5 mL (NDC 99101010105) and 10 mL (NDC 99101010110). Contract tiers set the allocation order (approval APR-14D2A743; allocations AL-D570A661, AL-CEC5 …
  - → {"task_id": "CRM-D81F1D82", "status": "open"}
### Turn 15
> 💭 I'm reconsidering what "contracted account" actually means here—whether it strictly refers to accounts holding a supply contract (5 of them) versus the broader set of 18 top-level accounts. This matters for BR-CUST-01, since clinics that are independent without a supply contract might not qualify for notification under that rule.  I'll settle on treating the 5 supply-contract accounts as the ones requiring individual CRM notifications, noting in the report that other non-contracted accounts weren't individually notified, with wholesalers handled separately via Trade Relations. I'm also planning additional CRM cases: one to Trade Relations for W-01/W-02 escalation, one to Medical Affairs for therapeutic alternatives, and one to Supply Planning covering lens care, the revised ship date from S-104, and expediting qualification of S-131.  

- 🔧 `create_escalation_case` {"owner": "TRADE_RELATIONS", "subject": "Notify wholesalers W-01 and W-02: Lacrivia supply delay from DC-EAST", "details": "The EDI gateway has no API (send_wholesaler_edi is no_api), so this is handed to Trade Relations per SDR-4.2. Please tell the wholesalers served by DC-EAST: Keystone Drug Distributors (W-01) and Atlas Pharma Supply (W-02). Cause: supplier S-104 (Delmar) will miss its 2026-10- …
  - → {"case_id": "CASE-8D8F0C47", "status": "open", "owner": "TRADE_RELATIONS"}
- 🔧 `create_escalation_case` {"owner": "Medical Affairs", "subject": "Lacrivia shortage at DC-EAST \u2013 no approved company substitute; guidance on therapeutic alternatives needed", "details": "Per BR-SUB-01 and BR-SUB-02: Lacrivia 0.1% 5 mL and 10 mL are both below safety stock at DC-EAST, so there is no same-brand pack to switch to. The approved company substitute, Cyclosporine OS 0.05% (FG-1003), also depends on the fail …
  - → {"case_id": "CASE-1ABA63F9", "status": "open", "owner": "Medical Affairs"}
- 🔧 `create_escalation_case` {"owner": "Supply Planning", "subject": "S-104 RM-221 delay: revised ship date, S-131 qualification, lens-care exposure not visible in DC inventory", "details": "1) S-104 (Delmar) will miss the 2026-10-07 promised ship of PO005791 (RM-221, 4,200). PO000369 (RM-221, 3,300, due 2026-10-29) is also at risk. Please get a revised ship date from the supplier: recovery at the DC equals ship date + 50 day …
  - → {"case_id": "CASE-3F9D947A", "status": "open", "owner": "Supply Planning"}
### Turn 16
> 💭 I made a claim about dropping below threshold before recovery without actually verifying it — looking at DC-CENTRAL FG-1001, 677 vs SS 314 suggests recovery at 57+ days, so it's likely true but unconfirmed. I'll flag this as an unverified point in the final report rather than state it as fact.  

- 🔧 `log_execution` {}
  - → {"trace_id":"55b97192-369d-4ff5-9cb8-afad084c90ad","followed":["SDR-2.1","SDR-1.2","SDR-2.4","SDR-3.2","SDR-3.3","SDR-4.1","SDR-4.2"],"seeded_asset":null}

## Final report

S-104's late shipment hits Lacrivia hardest at the East distribution centre (DC-EAST), which has only 1–2 days of stock left. I sent the 80 units there to the three Tier A health systems under an approved allocation. No alternate supplier or company substitute is available. Supply can't recover before 2026-11-26.

No trusted playbook matched, so I followed the Supply Disruption Response process (SDR-1.1 to 5.1).

**What I found**
- **The late order:** the next ship date is purchase order PO005791 — 4,200 of Polysorbate 80 (RM-221), promised for 2026-10-07. S-104 has two more open orders: PO000369 (RM-221, 3,300, due 10-29) and PO000430 (RM-222, due 10-26).
- **Products affected:** RM-221 feeds Lacrivia 0.1% 5 mL and 10 mL (FG-1001/1002), Cyclosporine OS 0.05% 5 mL (FG-1003) and 11 lens-care products (FG-3001 to FG-3011). An older BOM link that has been replaced was ignored.
- **No backup supplier:** the only other supplier listed, S-131, is not qualified and not approved in the supplier portal. So I raised no purchase requisition.
- **Stock against safety stock (latest snapshot, 2026-09-25):**

| Pack | DC-EAST on hand | DC-EAST safety stock | Days of supply |
|---|---|---|---|
| Lacrivia 5 mL | 46 | 471 | about 1.3 |
| Lacrivia 10 mL | 34 | 233 | about 2.3 |

  DC-CENTRAL and DC-WEST are above safety stock on all three packs. Cyclosporine OS is also above safety stock at DC-EAST (615 vs 252).
- **Recovery:** it takes 50 days from the material shipping to stock reaching the DC (MES standard times; includes the 14-day sterility test). So recovery is no earlier than 2026-11-26, and later by however long S-104 slips.
- **Substitute (BR-SUB-01/02):** none. Both Lacrivia packs are short at DC-EAST, and Cyclosporine OS is made from the same material. Medical Affairs guides therapeutic alternatives.

**Actions taken**
1. **Approval APR-14D2A743 (approved):** the DC-EAST plan totals 80 units, $45,840 at list price, which is over the $25,000 threshold (BR-APPR-01).
2. **Allocations:** units are split by contract tier, then pro rata by 13-week prescription volume (TRx) from prescribers in DC-EAST states, 2026-07-03 to 09-25. Tier A used up all the stock (BR-ALLOC-01/02); no patient-level data was used.

| Allocation | Pack | Riverbend (AC00059) | Oak Hollow (AC00038) | Northfield (AC00117) |
|---|---|---|---|---|
| AL-D570A661 | 5 mL | 20 | 15 | 11 |
| AL-CEC5B4FE | 10 mL | 15 | 11 | 8 |

3. **Account team tasks:** CRM-ABB4BC05 (Riverbend), CRM-8AC7CC9F (Oak Hollow), CRM-921C2892 (Northfield), CRM-B57DA1E5 (Clearview, Tier B, none) and CRM-D81F1D82 (Sunridge, Tier B, none). Each covers the allocation, the recovery date and the lack of a substitute.
4. **CASE-8D8F0C47 (Trade Relations):** asks them to notify the wholesalers W-01 Keystone and W-02 Atlas. The wholesaler EDI channel has no API.
5. **CASE-1ABA63F9 (Medical Affairs):** guidance on therapeutic alternatives.
6. **CASE-3F9D947A (Supply Planning):**
   - get a revised ship date from S-104, and flag PO000369 as at risk;
   - consider speeding up S-131's qualification;
   - assess the lens-care products;
   - watch DC-CENTRAL and DC-WEST.

**Not done, and why**
- **Lens-care products:** they have no DC inventory data and no NDC in the commercial data, so I couldn't check them against safety stock or allocate them. Handed to Supply Planning.
- **Other accounts:** I didn't notify the accounts without a supply contract that prescribe Lacrivia in DC-EAST states (8 health-system or independent-clinic accounts). They get no units under the allocation rules, and I read the process step as covering contracted accounts only. The wholesalers are being told through Trade Relations.
- **Other DCs and Cyclosporine OS:** none is below safety stock, so nothing was allocated and there were no transfers between DCs.
- **RM-222 (PO000430):** not part of "the next ship date", so I didn't assess it.

**Assumptions**
- The miss affects PO005791, and S-104 hasn't given a new date, so the recovery date is a floor.
- I placed prescribers in a DC's region by their clinic's state. Riverbend (head office in CA) and the Minnesota health systems count only through their East-state clinics.
- Clearview's Tier B contract (expires 2026-12-31) is treated as still active.
- In the Supply Planning case I said DC-CENTRAL and DC-WEST will likely fall below safety stock before recovery. I didn't calculate that; it's an estimate.

**Knowledge-layer items used:** process Supply Disruption Response; rules BR-ALLOC-01/02, BR-APPR-01, BR-SUB-01/02, BR-LEAD-01, BR-CUST-01, BR-REGION-01, POL-DUA-01; reference sets supply_contracts, list_prices, dc_service_regions, approved_substitutes; and the ratified tables PURCH_ORD, SUPPLIER_MATERIAL, DC_INV, WHSLR_SHIP, PLANT_MATERIAL, RXT_WKLY, PRESCRIBER and ACCOUNT.

## Final state of the ops store (sandbox)

- **Allocation** AL-CEC5B4FE · DC-EAST · NDC 99101010110 · approval APR-14D2A743: AC00038 11, AC00059 15, AC00117 8
- **Allocation** AL-D570A661 · DC-EAST · NDC 99101010105 · approval APR-14D2A743: AC00038 15, AC00059 20, AC00117 11
- **Approval** APR-14D2A743 · allocation_plan · DC-EAST · $45,840 · approved by Supply Planning lead (oracle)
- **Case** CASE-8D8F0C47 → TRADE_RELATIONS: Notify wholesalers W-01 and W-02: Lacrivia supply delay from DC-EAST
- **Case** CASE-1ABA63F9 → Medical Affairs: Lacrivia shortage at DC-EAST – no approved company substitute; guidance on therapeutic alternatives needed
- **Case** CASE-3F9D947A → Supply Planning: S-104 RM-221 delay: revised ship date, S-131 qualification, lens-care exposure not visible in DC inventory
- **CRM tasks** (5): AC00001, AC00038, AC00059, AC00117, AC00138
